XLRN News and Press, Acceleron Pharma Inc. From 01/27/20

Shares of Acceleron Pharma (NASDAQ: XLRN) shot up significantly in after-hours trading on Monday when the company announced positive results for its drug to treat pulmonary arterial hypertension (PAH). A phase 2 clinical trial of Acceleron's drug candidate, sotatercept, met both the primary ...

Gainers: XLRN   +79.4% . SURF   +17.2% . DESP   +8.7% . KBWB   +5.8% . BCRX   +4.4% . More news on: Acceleron Pharma Inc., Surface Oncology, Inc., Despegar.com, Corp., Stocks on the move, , , News on ETFs Read more ...

Acceleron Pharma (NASDAQ: XLRN ) announces positive results from a Phase 2 clinical trial, PULSAR , evaluating sotatercept in patients with pulmonary arterial hypertension (PAH). More news on: Acceleron Pharma Inc., Healthcare stocks news, Stocks on the move, Read more ...

- The PULSAR trial achieved its primary endpoint: a statistically significant reduction in pulmonary vascular resistance - - The trial also achieved statistically significant improvements in the key secondary endpoint of six-minute walk distance (6MWD) and other secondary endpoints, in...

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that John Quisel, J.D., Ph.D, Executive Vice President and Chief Business Officer, is leaving the ...

The following slide deck was published by Acceleron Pharma Inc. in conjunction with this Read more ...

Data from MEDALIST showed significant clinical benefit of Reblozyl in treating anemia in adults with myelodysplastic syndromes Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the New England Journal of Medicine (NEJM) has publi...

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that senior management will participate at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California. On Monday, January 13, 2020, Habib Dable, Acceleron’s President and Chief Executive Officer, will present...

Shares of Bristol-Myers Squibb (NYSE: BMY) gained nearly 13% last month, according to data from  S&P Global Market Intelligence . The trek higher capped off a solid year for the industry leader, as the pharma stock gained 23.4% in 2019. The finish was all the more impressive consi...

Acceleron Pharma ( XLRN -0.7% ) inks a collaboration and license agreement with Fulcrum Therapeutics ( FULC ) aimed at identifying small molecules designed to modulate specific pathways associated with an undisclosed pulmonary disease indication. More news on: Acceleron Pharma Inc., Fu...